
Opinion|Videos|January 1, 2025
The Impact of Mutational Burden on Responses With Frontline Luspatercept in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss how mutational burden impacts the response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), highlighting its role in predicting treatment outcomes and the duration of transfusion independence.
Episodes in this series






































